

DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba,
Ahmedabad – 380 055

E-mail: dharachem99@yahoo.in

Date: 6th May, 2024

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai – 400 001.

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held today i.e. 6th May, 2024

Ref: Security Id: DPL/ Code: 543594

Pursuant to the second proviso to Regulation 30(6) of the SEBI (LODR) Regulations, 2015, we hereby inform you that the Board of Directors of the Company in their meeting held today i.e. Monday, 6th May, 2024 which commenced at 2:00 P.M. and concluded at 7:20 P.M. at the Registered Office of the Company situated at A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad - 380055, Gujarat inter-alia considered and approved:

1. Considered and approved the Split/ Sub-division of Equity Shares of the Company from face value of Rs. 10/- each to face value of Re. 1/- each subject to the approval of Shareholders of the Company. The record date for the Split/ Sub-division of Equity Shares will be intimated in due course. Other requisite details regarding the Split/ Sub-division of Equity Shares in terms of SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is attached herewith as **Annexure – I**.

Recommended alteration of Capital clause i.e. Clause V of the Memorandum of Association of the Company pursuant to the aforesaid Split/ Sub-division of Equity Shares, subject to the approval of the Shareholders of the Company in the General Meeting.

2. Increase in Authorised Share Capital upto Rs. 92,00,00,000/- by alteration of the capital clause in the Memorandum of Association of the Company.
3. Raising of funds upto Rs. 49.00 Crores by way of issue of Equity shares (hereinafter referred to as “**Shares**”), through preferential allotment against trade payables for consideration other than cash, as per Chapter V of SEBI (ICDR) Regulations, 2018, subject to approval of shareholders and other authorities concerned.
4. Raising of funds up to Rs. 18.00 Crores by way of issue of Warrants (hereinafter referred to as “**Convertible Warrants**”), through preferential allotment to the person(s) belonging to both Promoter & Promoter group and Non-Promoter category, as per Chapter V of SEBI (ICDR) Regulations, 2018, subject to approval of Shareholders and other authorities concerned.

*Other requisite details/ disclosures regarding the issuance of securities under Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circular Nos. CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is attached herewith as **Annexure – II**.*

DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba,
Ahmedabad – 380 055

E-mail: धारacheम99@yahoo.in

5. The decision to hold Extra-Ordinary General Meeting (EGM) for approval of the shareholders along with EGM notice and other relevant documents shall be submitted in due course.

Further, we hereby inform you that the Board of Directors has decided not to proceed with the proposal of Issue of Bonus Equity Shares to the existing Equity Shareholders of the Company.

Kindly take the same on your record and oblige us.

For, Dipna Pharmachem Limited

Keyur Shah
Managing Director
DIN: 03167258

DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba,
Ahmedabad – 380 055

E-mail: dharachem99@yahoo.in

Annexure – I

Details of Split/ Sub-division of shares – Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015:

1. Split/ Consolidation ratio:

1 (One) Equity Share of face value of Rs. 10/- each will be sub divided/ split into 10 (Ten) Equity Shares of face value of Re. 1/- each.

2. Rationale behind the Split/ Consolidation:

To enhance the liquidity of Equity shares in the capital market with higher floating stocks, widen shareholder base and make the Equity shares affordable to the small investors.

3. Pre and post share capital – Authorised, paid-up and subscribed:

Particulars	Pre-sub division of Equity Shares			Post-sub division of Equity Shares		
	No. of shares	Face Value (in Rs.)	Total Share Capital (in Rs.)	No. of shares	Face Value (in Rs.)	Total Share Capital (in Rs.)
Authorised Share Capital	2,50,00,000	10/-	25,00,00,000/-	25,00,00,000	1/-	25,00,00,000/-
Issued, Subscribed and Paid-up Share capital	2,40,45,250	10/-	24,04,52,500/-	24,04,52,500	1/-	24,04,52,500/-

4. Expected time of completion:

Within 6 months from the date of approval by the shareholders at their Extra-Ordinary General Meeting *(to be determined in due course)*.

5. Class of shares which are consolidated or sub-divided:

Equity shares of face value of Rs. 10/- each are proposed to be sub-divided (split) into Equity shares of face value of Re. 1/- each.

DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba,
Ahmedabad – 380 055

E-mail: धारारुकेड99@यहूड.ड

6. Number of shares of each class pre and post-split / consolidation:

Particulars	Pre-sub division of Equity Shares			Post-sub division of Equity Shares		
	No. of shares	Face Value (in Rs.)	Total Share Capital (in Rs.)	No. of shares	Face Value (in Rs.)	Total Share Capital (in Rs.)
Authorised Share Capital	2,50,00,000	10/-	25,00,00,000/-	25,00,00,000	1/-	25,00,00,000/-
Issued, Subscribed and Paid-up Share capital	2,40,45,250	10/-	24,04,52,500/-	24,04,52,500	1/-	24,04,52,500/-

7. Number of shareholders who did not get any shares in consolidation and their pre-consolidation shareholding:

Not Applicable.

DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba,
Ahmedabad – 380 055

E-mail: dharachem99@yahoo.in

Annexure - II

Sr. No.	Particulars	Details (Agenda No. 3)	Details (Agenda No. 4)
1.	Type of securities proposed to be issued (viz. equity shares, convertibles etc.)	Equity shares	Warrants convertible into equal number of Equity Shares
2.	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Preferential allotment to person(s)/ entity(ies) belonging to Non-Promoter category	Preferential allotment to person(s) belonging to both Promoter & Promoter group and Non-Promoter category
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	Approximately upto Rs. 49.00 Crores valued Equity shares	Approximately upto Rs. 18.00 Crores valued Convertible Warrants
4.	Name of Investors	As per Annexure - A	As per Annexure - A
5.	Post allotment of securities - outcome of the subscription, issue price/ allotted price (in case of convertibles), number of investors	Not Applicable	Not Applicable
6.	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	Not Applicable	Warrant shall be convertible into equal number equity shares within a maximum tenure of 18 months from the date of allotment of the warrants. As per SEBI (ICDR) Regulations, 2018, 25% of the total issue price shall be payable up-front and the balance 75% shall be paid before the exercise of option to convert the warrants into equity shares. In case the balance payment is not received with the maximum tenure of the warrants; the amount paid on the warrants shall get lapsed.

DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba,
Ahmedabad – 380 055

E-mail: धारारुनु99@yahuu.in

Annexure - A

Sr. No.	Name of Investors (Agenda No. 3)	Name of Investors (Agenda No. 4)
1.	Nim Chemicals	Dipna Keyur Shah
2.	Nextgen Pharmachem	Saumil Ashokbhai Shah
3.	Falguni Enterprise	Saurabh Kamlesh Shah
4.	Adinath Pharma Chem	Manan Vinodkumar Mody
5.	Arison Alkalies and Chemicals Private Limited	Jain Punit Shantilal
6.	MKS Alkalies and Chemicals Private Limited	Jitendra Kapilrai Joshi
7.	Siddharth Global Private Limited	Hardik Dilipkumar Mehta
8.	-	Jalpa Chiragkumar Jani